VANCOUVER, BRITISH COLUMBIA / TheNewswire / May 3, 2017 – the board of directors of BioHEP Technologies Ltd. (the “Company”) approved the Assignment and Assumption Agreement dated for reference April 21, 2017, between BioDE Ventures Ltd. (“BioDE”) and the Company (the “Assignment Agreement”).

Pursuant to the Assignment Agreement, BioDE assigned to the Company the Exclusive License Agreement effective as of December, 2005 between Migenix, Inc. and Cutanea Life Sciences, Inc. (the “License Agreement”) and certain patents (the “Patents”) for the price of $450,000 which will be paid by the Company by issuing 540,050 shares of the Company at a price of $0.833256 per share.

The value of the License Agreement and the Patents of BioDE was determined by an independent valuation consultant.

The value of the shares of the Company was determined by dividing the value of the main assets of the Company by the number of issued and outstanding shares of the Company.

The Assignment Agreement is subject to BioDE completing an amalgamation pursuant to the Amalgamation Agreement among the Company, Exro Technologies Inc. and 1089001 B.C. Ltd. dated for reference November 7, 2016.

ON BEHALF OF THE BOARD OF DIRECTORS

Chester Shynkaryk

Chief Executive Officer

BioDE Ventures Ltd.

2820 Granville Street

Vancouver, B.C.  V6C 1S4

Tel: (604) 722-9140